Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy.

MD Anderson Cancer Center, Dallas, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Dallas, TX
Treatments:ChemotherapyHospital:MD Anderson Cancer Center
Drugs:Journal:Link
Date:Apr 2008

Description:

Patients: This phase II study involved 32 patients with recurrent glioblastoma multiforme. The median age was 46.5 years, ranging from 21 to 65. The majority, 75%, were men.

Treatment: Patients were treated with the chemotherapy drugs irinotecan and thalidomide.

Toxicities: Two patients died from causes possibly related to treatment. Grade 4 neutropenia, lymphopenia, seizure, venous thromboembolism, and lymphopenia was reported. Grade 3 toxicities included leukopenia/neutropenia, diarrhea with abdominal cramping/pain.

Results: The median overall survival was 36 weeks (8.3 months) from the time the patients entered the study.

Support: This study was supported by research grants from Pfizer Pharmaceuticals and Celgene Corporation. Thalidomide is marketed by Celgene as Thalomid.

Correspondence: Dr. Vinay Puduvalli



Back